Natixis Advisors LLC Decreases Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

Natixis Advisors LLC decreased its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 4.9% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 84,143 shares of the medical research company's stock after selling 4,310 shares during the period. Natixis Advisors LLC owned 0.16% of Charles River Laboratories International worth $16,574,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Kayne Anderson Rudnick Investment Management LLC boosted its stake in Charles River Laboratories International by 1.7% during the second quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,908,989 shares of the medical research company's stock worth $394,359,000 after buying an additional 31,359 shares during the period. Allspring Global Investments Holdings LLC raised its holdings in shares of Charles River Laboratories International by 40.7% in the third quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company's stock valued at $346,821,000 after acquiring an additional 509,163 shares in the last quarter. Earnest Partners LLC raised its holdings in shares of Charles River Laboratories International by 12.4% in the second quarter. Earnest Partners LLC now owns 1,004,486 shares of the medical research company's stock valued at $207,507,000 after acquiring an additional 110,725 shares in the last quarter. Marshall Wace LLP raised its holdings in shares of Charles River Laboratories International by 24.6% in the second quarter. Marshall Wace LLP now owns 825,905 shares of the medical research company's stock valued at $170,615,000 after acquiring an additional 163,056 shares in the last quarter. Finally, Sei Investments Co. raised its holdings in Charles River Laboratories International by 8.6% in the second quarter. Sei Investments Co. now owns 624,800 shares of the medical research company's stock worth $129,072,000 after purchasing an additional 49,451 shares in the last quarter. Institutional investors own 98.91% of the company's stock.

Insider Buying and Selling at Charles River Laboratories International

In other news, Director Richard F. Wallman sold 6,621 shares of the stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the completion of the transaction, the director now directly owns 12,386 shares in the company, valued at approximately $2,676,862.32. This represents a 34.83 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.30% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

CRL has been the subject of a number of recent research reports. StockNews.com downgraded shares of Charles River Laboratories International from a "buy" rating to a "hold" rating in a report on Thursday, November 7th. TD Cowen boosted their price target on Charles River Laboratories International from $203.00 to $227.00 and gave the stock a "hold" rating in a research note on Monday, November 11th. Robert W. Baird dropped their price target on Charles River Laboratories International from $191.00 to $190.00 and set a "neutral" rating on the stock in a research note on Friday, September 20th. UBS Group boosted their price target on Charles River Laboratories International from $240.00 to $250.00 and gave the stock a "buy" rating in a research note on Thursday, November 7th. Finally, Citigroup lowered Charles River Laboratories International from a "neutral" rating to a "sell" rating and dropped their price target for the stock from $215.00 to $175.00 in a research note on Tuesday, October 1st. Three research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat, Charles River Laboratories International presently has an average rating of "Hold" and an average price target of $214.38.

Charles River Laboratories International Price Performance

Shares of CRL stock traded down $0.80 during trading hours on Wednesday, hitting $185.30. 367,541 shares of the company's stock were exchanged, compared to its average volume of 624,524. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61. The firm has a market cap of $9.48 billion, a P/E ratio of 23.29, a P/E/G ratio of 4.84 and a beta of 1.38. The firm has a 50 day moving average of $195.16 and a two-hundred day moving average of $206.56. Charles River Laboratories International, Inc. has a fifty-two week low of $176.48 and a fifty-two week high of $275.00.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The firm had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $975.99 million. During the same period in the prior year, the company earned $2.72 EPS. The firm's revenue was down 1.6% compared to the same quarter last year. Sell-side analysts forecast that Charles River Laboratories International, Inc. will post 10.19 EPS for the current year.

Charles River Laboratories International declared that its Board of Directors has approved a share repurchase plan on Wednesday, August 7th that permits the company to buyback $1.00 billion in shares. This buyback authorization permits the medical research company to repurchase up to 9.6% of its stock through open market purchases. Stock buyback plans are often a sign that the company's board of directors believes its stock is undervalued.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).